HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

1-aminocyclopentane-1,3,4-tricarboxylic acid

metabolic glutamate receptor (mGluR) antagonist; structure in first source

Also Known As:

ACPT acid; ACPT-I; ACPT-II

Networked: 9 relevant articles (2 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Cyclic Hydrocarbons: 97
    - Alicyclic Hydrocarbons: 1
      - Cycloparaffins: 6
        Cyclopentanes: 58
        1-aminocyclopentane-1,3,4-tricarboxylic acid: 9
- Carboxylic Acids: 973
  - Acyclic Acids
    - Tricarboxylic Acids: 423
      - 1-aminocyclopentane-1,3,4-tricarboxylic acid: 9

Experts

1.	Boguszewski, Paweł M: 2 articles (01/2018 - 03/2016)
2.	Domin, Helena: 2 articles (01/2018 - 03/2016)
3.	Kozniewska, Ewa: 2 articles (01/2018 - 03/2016)
4.	Przykaza, Łukasz: 2 articles (01/2018 - 03/2016)
5.	Śmiałowska, Maria: 2 articles (01/2018 - 03/2016)
6.	Pilc, A: 2 articles (09/2015 - 09/2008)
7.	Amalric, Marianne: 2 articles (09/2008 - 06/2007)
8.	Lopez, Sebastien: 2 articles (09/2008 - 06/2007)
9.	Turle-Lorenzo, Nathalie: 2 articles (09/2008 - 06/2007)
10.	Acher, Francine: 2 articles (07/2008 - 06/2007)

Related Diseases

1.	Infarction (Infarctions) 01/01/2018 - "We determined that ACPT-I not only reduced the cortico-striatal infarction but also improved several gait parameters (run speed, run and stand durations, swing speed and stride length) and mobility when administered 30 min after the start of the occlusion or 30 min after the start of reperfusion. " 03/01/2016 - "In the rat MCAO model, we demonstrated that ACPT-I (30 mg/kg) injected intraperitoneally either 30 min after starting MCAO or 30 min after beginning reperfusion not only diminished the infarction volume by about 30%, but also improved selected gait parameters (CatWalk analysis) and the mobility of animals in the open field test. "
2.	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 01/01/2018 - "Our previous studies have shown that ACPT-I [(1S, 3R,4S)-1-aminocyclopentane-1,2,4-tricarboxylic acid], a blood-brain barrier permeable agonist of group III metabotropic glutamate (mGlu) receptors, was neuroprotective against middle cerebral artery occlusion/reperfusion (MCAO/R) in normotensive rats. " 03/01/2016 - "In the present study, we investigated the effect of ACPT-I [(1S, 3R,4S)-1-aminocyclopentane-1,2,4-tricarboxylic acid], a blood-brain-barrier permeable agonist of group III mGlu receptor, against oxygen-glucose deprivation (OGD)-evoked neuronal cell death in primary neuronal cell cultures and in the model of transient middle cerebral artery occlusion (MCAO) in rats. "
3.	Ischemic Stroke 03/01/2016 - "Neuroprotective potential of the group III mGlu receptor agonist ACPT-I in animal models of ischemic stroke: In vitro and in vivo studies." 01/01/2018 - "Neuroprotective effect of the group III mGlu receptor agonist ACPT-I after ischemic stroke in rats with essential hypertension."
4.	Stroke (Strokes) 01/01/2018 - "Preclinical studies are typically performed on healthy animals, whereas stroke patients predominately exhibit comorbidities, such as hypertension; therefore, in the present study, we investigated the effect of ACPT-I in spontaneously hypertensive rats (SHR) after MCAO/R. "
5.	Psychotic Disorders (Schizoaffective Disorder) 09/01/2008 - "In this work, we choose to study an agonist of group III mGlu receptors (1S,3R,4S)-1-aminocyclo-pentane-1,3,4-tricarboxylic acid (ACPT-I) using intraperitoneal administration in three animal behavioral models predictive of psychosis or hallucinations. "

Related Drugs and Biologics

1.	Tricarboxylic Acids
2.	Glutamic Acid (Glutamate)
3.	Oxygen (Dioxygen)
4.	Glucose (Dextrose)
5.	Acids
6.	Haloperidol (Haldol)
7.	Staurosporine
8.	Neuroprotective Agents
9.	Vincristine (Oncovin)
10.	Tretinoin (Retinoic Acid)

Related Therapies and Procedures

1.	Spinal Injections